Of note, a drawback of this method is that it evaluates bulk CTCs and determines the average HER2 expression of all tumor cells, so it cannot capture HER2 heterogeneity, which, in contrast, would require evaluation of individual cells. Here, ERBB2 is linked to neoplasm.